Tirzepatide vs MOTS-c
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.
Full details →Side-by-Side Comparison
| Aspect | Tirzepatide | MOTS-c |
|---|---|---|
| Mechanism | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. | Activates AMPK pathway, enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and regulates mitochondrial function. Acts as a metabolic hormone affecting whole-body energy homeostasis. |
| Typical Dosage | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. | Research protocols typically use 5-10mg administered subcutaneously several times per week. Optimal dosing not yet established. |
| Administration | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. | Subcutaneous injection. Often combined with exercise protocols as it enhances exercise capacity and metabolic adaptation. |
| Side Effects | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. | Limited human data. Animal studies show good tolerability. May affect energy levels and exercise performance. |
| Best For |
What They Have in Common
Both Tirzepatide and MOTS-c are commonly used for: